59224-23-6Relevant articles and documents
The crystal structure and cytotoxicity of centrosymmetric copper(II) complex derived from S-methyldithiocarbazate with isatin
Manan, Mohd Abdul Fatah Abdul,Tahir, M. Ibrahim M.,Crouse, Karen A.,Rosli, Rozita,How, Fiona N.-F.,Watkin, David J.
, p. 1866 - 1871 (2011)
Copper(II) complex of S-methyldithiocarbazate with isatin has been prepared and screened for their cytotoxic activities against MCF-7 (Human non-metastatic mammary gland adenocarcinoma cell line) and MDA-MB-231 (Human metastatic mammary gland adenocarcinoma cell line). The compound crystallized in an orthorhombic crystal system with a space group C 2cb and was found to be selectively active against MCF-7 cell line (Human nonmetastatic mammary gland adenocarcinoma cell line with an IC50 value 0.45 μg/mL. The crystal structure of this centrosymmetric Cu(SMISA)2 complex (SMISA = Schiff base formed by condensation reaction of S-methyldithiocarbazate with isatin) showed that the copper atom has a distorted square-planar geometry with the Schiff base coordinated to the metal ion as a uninegatively charged bidentate ligand through the azomethine nitrogen and thiolate sulfur. Springer Science+Business Media, LLC 2011.
Design, synthesis and anticancer activity of piperazine hydroxamates and their histone deacetylase (HDAC) inhibitory activity
Chetan, Bhadaliya,Bunha, Mahesh,Jagrat, Monika,Sinha, Barij Nayan,Saiko, Philipp,Graser, Geraldine,Szekeres, Thomas,Raman, Ganapathy,Rajendran, Praveen,Moorthy, Dhatchana,Basu, Arijit,Jayaprakash, Venkatesan
supporting information; experimental part, p. 3906 - 3910 (2010/09/03)
Six compounds were synthesized with piperazine in linker region and hydroxamate as Zinc Binding Group (ZBG). They were screened against three cancer cell-lines (NCIH460; HCT116; U251). Compounds 5c and 5f with GI50 value of 9.33 ± 1.3 μM and 12.03 ± 4 μM, respectively, were tested for their inhibitory potential on hHDAC8. Compound 5c had IC50 of 33.67 μM. Compounds were also screened for their anticancer activity against HL60 human promyelocytic leukemia cell line due to the presence of pharmacophoric features of RR inhibitors in them. Compound 5c had IC 50 of 0.6 μM at 48 h.